secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2022-12-12T23:59:59+00:00
Accession:  0001619856-22-000036
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caribou: 12-month CB-010 data shows durable CR in 2/6; selects ROR1 for CB-020
------------------------------------------------------------------------------

- CB-010 ANTLER cohort 1: 6/6 CR best response; 3/6 durable CR at 6 months; 2/6 maintain CR at 12 months; longest CR 18 months.
- FDA granted CB-010 RMAT and Fast Track designations; dose level 2 (80x10^6) no DLTs; enrolling dose level 3 (120x10^6).
- Selected ROR1 as target for CB-020 iPSC-derived allogeneic CAR-NK cell therapy; preclinical data shows significant tumor burden reduction in xenograft model.
- Armoring strategies for CAR-NK platform: CBLB knockout, B2M knockout with HLA-E insertion, membrane-bound IL-15/IL-15RA fusion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000161985622000036/0001619856-22-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000161985622000036/crbu-20221212.htm
  HTML page:      https://secwatch.observer/filing/0001619856-22-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer